Research guide

Retatrutide (LY3437943): Research Guide

Retatrutide is a single synthetic peptide that switches on three different receptors at once — GIP, GLP-1 and glucagon. Compounds studied in this area more commonly engage one receptor, or two. It is not approved by any regulator. This guide sets out what the published literature has examined, with an identifier for every study named.

Identifiers

Common name
Retatrutide
Development code
LY3437943
Compound class
Synthetic peptide; triple receptor agonist
Receptor targets
GIPR, GLP-1R, GCGR (Coskun et al., 2022)
Originator
Eli Lilly and Company
First peer-reviewed description
Cell Metabolism, 2022
Regulatory status
Investigational. Not approved by the FDA, the EMA or any other major regulator as of August 2026
Supplied by Prime Peptides UAE as
10mg and 20mg research pen — Retatrutide product page

What retatrutide is

Most peptides in this field are built to do one thing to one receptor. Retatrutide was built to do three.

The three targets sit on different arms of metabolic signalling. GIP and GLP-1 are the incretin receptors — the pair that respond to nutrient arrival in the gut, and the ones that a decade of pharmacology has concentrated on. The glucagon receptor is the odd one out, and it is the reason this compound is discussed separately from the rest of the field: it belongs to the same metabolic system but is associated with energy expenditure rather than with appetite signalling.

Coskun and colleagues described the molecule under its development code, LY3437943, in Cell Metabolism in 2022 (PMID 35985340), reporting its discovery, its receptor pharmacology, work in obese mouse models, and a first-in-human phase 1 evaluation. That paper set out the design rationale the field has worked from since: combine the three arms in one molecule rather than co-formulate separate agonists. In the cell assays reported there, the three activities are not evenly matched — activity at the GIP receptor is the strongest of the three.

One word is worth being precise about, because three similar-sounding classes get collapsed constantly. An agonist binds a receptor and activates it. An analogue is a structural variant of a natural peptide. A secretagogue prompts release of a hormone the body already makes, rather than acting on the downstream receptor itself. Retatrutide is described throughout the literature as an agonist, at all three named receptors. More of these are collected in the research peptide terminology glossary.

Where retatrutide sits among the incretin-receptor agonists

This class is grouped by a single number: how many receptors one molecule engages.

  • Single-receptor agonists act at GLP-1R alone. Semaglutide is the widely studied example.
  • Dual-receptor agonists act at GIPR and GLP-1R. Tirzepatide is the widely studied example.
  • Triple-receptor agonists add GCGR. Retatrutide is the compound in this class with the largest published trial record.

This is a taxonomy of mechanism, and nothing in it ranks the named compounds against one another. Naming them locates retatrutide inside a literature readers will already have met under other names. Where a controlled comparison exists, it exists in a trial: Rosenstock and colleagues (The Lancet, 2023, PMID 37385280) included an active comparator arm, which is the appropriate place to look for a comparison drawn under controlled conditions rather than asserted on a web page.

What the published literature has examined

Chronological. Each entry states what a study set out to examine and where it was published.

Magnitudes are deliberately omitted throughout — this guide states what was studied and which way it came out, not what was measured. Identifiers are given so the primary sources can be read directly.

Discovery and initial characterisation, 2022

Coskun and colleagues, Cell Metabolism (PMID 35985340). The first peer-reviewed description of the compound: receptor pharmacology, work in obese mouse models covering body-weight and glycaemic endpoints, and a first-in-human phase 1 evaluation. This is the paper that establishes what retatrutide is, and it is the correct citation for any statement about its mechanism.

Phase 1b in type 2 diabetes, 2022

Urva and colleagues, The Lancet (PMID 36354040). A randomised, double-blind, placebo-controlled multiple-ascending study across four United States centres in 72 participants with type 2 diabetes, with an active comparator arm, over twelve weeks. Pharmacokinetics, tolerability and metabolic endpoints were assessed. This is the study that established the human pharmacokinetic profile the later trials were designed around.

Phase 2 in obesity, 2023

Jastreboff and colleagues, New England Journal of Medicine (PMID 37366315). A double-blind, randomised, placebo-controlled phase 2 trial in 338 adults over 48 weeks. The primary endpoint was percentage change in body weight from baseline to 24 weeks, and the trial reported a statistically significant reduction relative to placebo. This is the most-cited retatrutide publication, and it is what most commentary in this category is ultimately referring to, usually without naming it.

Phase 2 in type 2 diabetes, 2023

Rosenstock and colleagues, The Lancet (PMID 37385280). A randomised, double-blind, placebo- and active-controlled, parallel-group phase 2 trial in 281 United States adults with type 2 diabetes, mean age 56.2 years, over 36 weeks. The named primary endpoint was change in HbA1c at 24 weeks. Glycaemic and body-weight endpoints were both assessed, and the inclusion of an active comparator is what distinguishes this trial from the obesity phase 2.

Phase 2a in metabolic dysfunction-associated steatotic liver disease, 2024

Sanyal and colleagues, Nature Medicine (PMID 38858523). A randomised, double-blind, placebo-controlled phase 2a trial in 98 participants, with mean relative change in liver fat at 24 weeks as the named primary endpoint, across a 48-week study. This trial extended the research question from body weight and glycaemia into hepatic endpoints.

The phase 3 TRIUMPH programme, 2025–2026

Giblin and colleagues, Diabetes, Obesity and Metabolism, 2026 (PMID 41090431), published the rationale and design of the registrational programme: four phase 3 trials. TRIUMPH-1 and TRIUMPH-2 are weight-management trials with nested obstructive sleep apnoea and knee osteoarthritis sub-studies; TRIUMPH-3 is a weight-management trial in populations with cardiovascular disease; TRIUMPH-4 is a standalone knee osteoarthritis trial. TRIUMPH-1 is registered as NCT05929066 and TRIUMPH-4 as NCT05931367 on ClinicalTrials.gov. The TRIUMPH-1 registration records Eli Lilly and Company as lead sponsor, a phase 3 design, 2,335 enrolled participants, an overall status of completed, and obesity, overweight, knee osteoarthritis and obstructive sleep apnoea as the conditions studied.

Eli Lilly announced topline findings from TRIUMPH-4 in December 2025, from TRIUMPH-1 in May 2026, and from TRIUMPH-2 and TRIUMPH-3 in July 2026. As of August 2026 those announcements are corporate disclosures, not peer-reviewed publications — and the distinction is worth more than it usually gets. A press release has not been through peer review. The full trial reports, with their pre-specified analyses, their adverse-event tables and their limitations sections, are the documents worth waiting for. A design paper is cited above rather than a press release because the design paper is the peer-reviewed source. This guide will be updated when the reports appear.

Where the evidence has been synthesised

Abouelmagd and colleagues, Proceedings (Baylor University Medical Center), 2025 (PMID 40291085), pooled three randomised controlled trials totalling 878 participants across body-weight, glycaemic, blood-pressure and adverse-event endpoints, and reported the pooled estimates for body weight, glycated haemoglobin and blood pressure as each statistically significant.

Worth stating rather than glossing: no pooled endpoint in that synthesis came out non-significant, and three trials is a small evidence base to pool. A meta-analysis in which nothing comes out null says more about how early a literature is than about the weight of what was found.

Regulatory status

Retatrutide is investigational. As of August 2026 it has not been approved by the United States Food and Drug Administration, the European Medicines Agency, or any other major regulator, for any indication. The phase 3 programme has reported topline findings by corporate announcement across its four trials; the peer-reviewed reports are not yet published, and no regulatory submission has been confirmed.

Prime Peptides UAE supplies retatrutide as a research material only. It is not supplied as a medicine, and nothing in the literature summarised above changes that.

What this literature does not establish

Published research attaches to a compound. It does not attach to a vial.

Literature describing retatrutide as a molecule establishes nothing about the identity, purity, quality or suitability of any particular material sold under that name — including this one. Those are separate questions, answered by a third-party lab report rather than by citation. A guide that blurs the two is doing something dishonest, however carefully it is worded.

Three specific limits are worth stating:

  1. The peer-reviewed human record is phase 2. The phase 3 programme has reported by press release; the peer-reviewed phase 3 reports are not yet published.
  2. Trial populations were specific. Each study above enrolled a defined population under defined criteria. A finding in a trial population is not a general statement about anyone else.
  3. A published trial says nothing about a research material’s provenance. The document that speaks to a specific material is its lab report — what one contains, and what it cannot establish, is covered in how to read a peptide COA.

How Prime Peptides UAE documents retatrutide

A third-party lab report is published for the 20mg unit and is available in full, with the issuing laboratory’s verification key, on Testing and Quality — where the reports we hold are published, and the products we hold none for are named. Format, strength, AED price and current document status for this item are on the Retatrutide product page.

This guide is a summary of published research. It contains no amounts, no schedules, no preparation or handling information, and no medical advice.

For research purposes only. Not for human consumption.

Prime Peptides UAE supplies this compound as a laboratory research material. Full regulatory information: Product and Regulatory Information.

Common questions

What is retatrutide?

Retatrutide, development code LY3437943, is an investigational synthetic peptide that acts as a single-molecule agonist at three receptors: GIPR, GLP-1R and GCGR. It was first described in the peer-reviewed literature by Coskun and colleagues in Cell Metabolism in 2022 (PMID 35985340). It is not approved by any regulator.

What does “triple agonist” mean here?

One molecule activates three separate receptors rather than one. For retatrutide those are the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor and the glucagon receptor. Coskun and colleagues (Cell Metabolism, 2022) describe the mechanistic rationale for combining the three in a single peptide.

Is retatrutide approved by any regulator?

No. As of August 2026 retatrutide is investigational and has not been approved by the FDA, the EMA or any other major regulator, for any indication. Its phase 3 registrational programme, TRIUMPH, is described by Giblin and colleagues in Diabetes, Obesity and Metabolism, 2026 (PMID 41090431).

What is the TRIUMPH programme?

Eli Lilly’s four-trial phase 3 registrational programme: two weight-management trials with nested obstructive sleep apnoea and knee osteoarthritis sub-studies, one weight-management trial in populations with cardiovascular disease, and one standalone knee osteoarthritis trial. The design paper is PMID 41090431; TRIUMPH-1 is NCT05929066 and TRIUMPH-4 is NCT05931367.

How does retatrutide differ from tirzepatide?

By the number of receptors a single molecule engages. Tirzepatide is described in the literature as a dual agonist at GIPR and GLP-1R; retatrutide adds the glucagon receptor, GCGR, as a third target (Coskun et al., Cell Metabolism, 2022). That is a mechanistic distinction, not a comparison of performance.

Does Prime Peptides UAE publish a lab report for retatrutide?

Yes, for the 20mg unit. It is published in full on Testing and Quality with the issuing laboratory’s verification key, and the document status for each item is stated on the Retatrutide product page. What a report can and cannot establish is explained in how to read a peptide COA.

What does “research use only” mean for this compound?

The material is supplied for laboratory research and is not supplied for human consumption. It is not a medicine and is not approved as one. Prime Peptides UAE supplies retatrutide as a research material only.

References

Publication identifiers verified against PubMed; registry identifiers against ClinicalTrials.gov.

  1. Coskun T, et al. Cell Metabolism. 2022;34(9):1234–1247.e9. Discovery, receptor pharmacology, preclinical characterisation and first-in-human evaluation of LY3437943. PMID 35985340 · DOI 10.1016/j.cmet.2022.07.013
  2. Urva S, et al. The Lancet. 2022;400(10366):1869–1881. Phase 1b multiple-ascending study in type 2 diabetes; pharmacokinetics and metabolic endpoints. PMID 36354040 · DOI 10.1016/S0140-6736(22)02033-5
  3. Jastreboff AM, et al. New England Journal of Medicine. 2023;389(6):514–526. Phase 2 randomised double-blind placebo-controlled trial in adults with obesity. PMID 37366315 · DOI 10.1056/NEJMoa2301972
  4. Rosenstock J, et al. The Lancet. 2023;402(10401):529–544. Phase 2 randomised, double-blind, placebo- and active-controlled, parallel-group trial in adults with type 2 diabetes. PMID 37385280 · DOI 10.1016/S0140-6736(23)01053-X
  5. Sanyal AJ, et al. Nature Medicine. 2024;30(7):2037–2048. Phase 2a randomised double-blind placebo-controlled trial in metabolic dysfunction-associated steatotic liver disease. PMID 38858523 · DOI 10.1038/s41591-024-03018-2
  6. Abouelmagd AA, et al. Proceedings (Baylor University Medical Center). 2025;38(3):291–303. Systematic review and meta-analysis of three randomised controlled trials. PMID 40291085 · DOI 10.1080/08998280.2025.2456441
  7. Giblin K, et al. Diabetes, Obesity and Metabolism. 2026;28(1):83–93. Rationale and design of the four-trial TRIUMPH phase 3 programme. PMID 41090431 · DOI 10.1111/dom.70209
  8. ClinicalTrials.gov registry records NCT05929066 (TRIUMPH-1) and NCT05931367 (TRIUMPH-4).